MRNA - Moderna Inc

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

52W High

$79.96

52W Low

$23.15

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.93

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

32.47

EV/EBITDA (<8 favorable)

4.64

EV/Revenue (<3 favorable)

1.77

P/S (TTM) (<3 favorable)

3.18

P/B (<3 favorable)

1.04

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.24%

Institutions (25–75% balanced)

74.91%

Shares Outstanding

389,080,000

Float

363,288,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

3,078,000,000

Gross Profit (TTM)

-2,199,000,064

EPS (TTM)

-7.51

Profit Margin (>10% good)

-0.94%

Operating Margin (TTM) (higher better)

-6.39%

ROE (TTM) (>15% strong)

-0.28%

EPS YoY (Quarterly) (>10% good)

-0.85

Revenue YoY (Quarterly) (>8% good)

-0.41

Momentum

Bearish momentum

Value

-1.2847

-1.3310

Trend

Rising

Signal Cross

No cross

As of

Sep. 09, 2025